ArticleTherapeutic advances in medical oncology2025
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is currently a lack of sufficient evidence on the prognosis of human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer (MIBC) and whether chemotherapy (CT) and targeted therapy can bring benefits. Objectives: To explore the prognosis and treatment of HER2-positive MIBC. Design: A retrospective multicenter study. Methods: In this multicenter real-world study, we consecutively enrolled patients who received local management and were diagnosed with lymph node-negative HER2-positive MIBC from January 2010 to December 2020. Results: A total of 163 patients were included. Thirty-nine patients (23.9%) received adjuvant CT, of which 12 patients (7.4%) received CT combined with trastuzumab. One patient received trastuzumab therapy alone. In total, nine patients (5.5%) experienced recurrence, and the 3-year disease-free survival (DFS) rate and 5-year DFS rate were both 95.1%. Kaplan-Meier analysis showed that patients aged ⩽40 had worse outcomes than those aged >40 (3-year DFS rate 81.8% vs 96.1%, Conclusion: HER2-positive MIBC has relatively good prognosis, and age ⩽40 years might be a poor prognostic factor. CT or targeted therapy seemed to bring little benefit for MIBC. Further prospective studies are needed to assess potential benefits of management for MIBC patients under the age of 40 years in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.